Posts by Sandra Ansanay-Alex
Four Swiss🇨🇭 start-ups in the Top 18 European TechBio companies
ONWARD, Haya Therapeutics, Retinai and Engimmune Therapeutics are in the top 18 Biotech companies in Europe according to investors. Stuck in the middle… raising funds can be hard for biotech start-ups… Biotech investors may not get the tech bit, while tech investors don’t get the bio bit. Sifted asked investors who ventured into the TechBio world…
Read MoreVolumina Medical closes its Series A funding to develop Adipearl
Clinique La Prairie and Skyviews Life Science Ltd are among the new investors Volumina Medical, a spin-off from the Swiss Federal Institute of Technology in Lausanne (EPFL) specializing in developing innovative biomaterials announced that it has raised an undisclosed amount in a Series A fundraising. Around 2 million women are diagnosed with breast cancer…
Read MoreThree new buildings on the Biopôle site in Lausanne
Biopôle SA announces a new partnership with Edmond de Rothschild Real Estate SICAV for the construction of three new buildings dedicated to Life Sciences. The work will start in December 2022 in Épalinges. This new 23,000-m2 complex, distributed over three buildings, will host up to 500 people and has been designed to house both…
Read MoreiOnctura, EBAMed and Terapet awarded by the Fongit
Fongit, the Fondation Genevoise pour l’Innovation Technologique, has just announced the latest beneficiaries of the Fongit Innovation Fund (FIF). iOnctura is awarded a growth loan of CHF 400,000. EBAMed and Terapet receive each a seed loan of CHF 100,000. The Fongit Innovation Fund The FIF is the instrument for fostering innovation and the…
Read MoreFuture of Health: 10 digital healthcare start-ups awarded
EPFL Innovation Park and CSS present the 2022 cohort The Future of Health Grant programme to support innovation in digital healthcare has been launched. The ten selected start-ups will benefit from funding and know-how to help them accelerate the development of their solutions. A whole ecosystem of partners and experts in digital healthcare is…
Read MoreNanolive SA closes a series C round at $22.2 million
After the successful closing of a US $22.2 million Series C equity financing, Nanolive announces the appointment of two extraordinary women to its board of directors: Dr. Deborah Birx and Mrs. Victoria Wang. Nanolive, based in canton de Vaud (Switzerland), develops cutting edge state-of-the-art label-free live cell digital analytical solutions to provide researchers and…
Read MoreHedera Dx raises €14 million in seed funding
The Swiss companies wants to accelerate the adoption of liquid biopsies for cancer testing Swiss techbio company Hedera Dx, based in Biopôle Lausanne and founded in 2021 by veteran healthcare entrepreneurs and executives, will be launching this fall a blood-based testing solution to profile cancer DNA circulating in the blood, helping patients access better…
Read MoreIncepto raised €27 million
The platform for artificial intelligence solutions applied to medical imaging, announces a €27 million round of financing. The goal: to treat one million patients in Europe per month by 2024. Incepto, which has a branch office at the Biopôle Lausanne in Switzerland, has just raised €27 million in a financing round led by LBO…
Read MoreOnward Confirms Amazing Results to restore Arm and Hand Function in People With Spinal Cord Injury
The Up-LIFT study evaluating ARC-EX Therapy demonstrated the effectiveness of the device to improve extremity strength and function in people with movement disabilities. The Up-LIFT study The Up-LIFT study is a prospective, single-arm pivotal study designed to evaluate the safety and effectiveness of non-invasive electrical spinal cord stimulation (ARC-EX Therapy) to treat upper extremity…
Read MoreSelexis and NexImmune Sign an Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers
This Agreement supports the development of molecules targeting acute myeloid leukemia, multiple myeloma, human papillomavirus (HPV) associated tumors, and additional human leukocyte antigens (HLAs) that have the potential to increase immunotherapy options for patients Selexis SA, a JSR Life Sciences company based in Geneva Switzerland, and NexImmune Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company…
Read More